Advance-ruling mechanism governs pending GST classification, exemption and taxability disputes, limiting writ review once the specialised forum functi...
Charitable trust income application permits verified capital expenditure but rejects deferred pre-operative claims and requires reconsideration of con...
Reinsurance premium deductions require established regulatory breaches, while independently acquired software qualifies within the computer depreciati...
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
Note: It is a system-generated summary and is for quick reference only.